Dyadic International (DYAI) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 revenue came in at $449,101, a 61.4% decline from $1,164,617 a year earlier, driven by lower grant revenue and fewer research and development (R&D) collaboration projects.
• Net loss narrowed to $1.36 million, or $(0.04) per share, compared with $1.98 million, or $(0.06) per share, in the prior-year quarter.
• Earnings per share (EPS) of $(0.04) missed the consensus estimate of $(0.03), while revenue of roughly $0.45 million fell well short of consensus near $1.43 million.
• Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase I (deoxyribonuclease I), an early validation of its commercialization strategy.
• Partner Inzymes commercialized a second chymosin product, unlocking an expected $225,000 contractual payment set to be recognized in the fourth quarter of 2026.
• For additional detail on Dyadic's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for more in-depth coverage.
• Interested in automated market insights? Explore Trending AI Robots to discover data-driven trading ideas.

Earnings Context and Why It Matters

Dyadic International, Inc., now doing business as Dyadic Applied BioSolutions, is a biotechnology company focused on producing high-value recombinant proteins through its proprietary C1 and Dapibus gene expression platforms. The third quarter of 2026 carries particular weight because it represents the company's ongoing transition from a development-stage platform toward a commercial, product-driven business. Investors are watching closely whether early product launches, distribution partnerships, and profit-sharing arrangements can offset a structural decline in grant and collaboration revenue. With revenue concentrated in a handful of emerging products and partnerships, this report offers a clear gauge of how quickly Dyadic's commercialization efforts are translating into recurring sales and whether its cost discipline is keeping losses in check.

Reported Results

For the quarter ended September 30, 2026, Dyadic reported total revenue of $449,101, down 61.4% from $1,164,617 in the same period a year earlier. The decline reflected a $538,199 drop in grant revenue tied to lower activity under Gates Foundation and CEPI (Coalition for Epidemic Preparedness Innovations) grants, along with a $187,728 decrease in R&D revenue as several collaboration projects concluded.

The company posted a net loss of $1,357,041, or $(0.04) per share, an improvement from $1,976,012, or $(0.06) per share, in the prior-year quarter. EPS of $(0.04) missed the consensus estimate of $(0.03) by one cent, while revenue of about $0.45 million fell far short of consensus estimates near $1.43 million. A non-cash gain of $545,527 from the change in fair value of a warrant liability helped cushion the bottom line.

Operating expenses declined across the board. R&D expenses fell 24.8% to $429,945, while general and administrative (G&A) expenses decreased 2.1% to $1,450,750. Loss from operations narrowed 5.9% to $1,812,365.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener supports the identification of trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. For investors tracking biotech names like Dyadic International, the AI Screener offers a structured way to surface comparable opportunities across the sector.

Market Reaction and Investor Sentiment

Dyadic's third-quarter results fell short of Wall Street's top-line expectations, with revenue of roughly $0.45 million coming in well below consensus near $1.43 million. The bottom-line result of $(0.04) per share also missed the $(0.03) consensus by a penny, though the net loss still narrowed on a year-over-year basis. Investor sentiment remains cautious: Dyadic's stock closed at $0.35 on the reporting day and has declined roughly 55% over the past three months and more than 60% over the past twelve months, reflecting broader concerns about the pace of commercialization. The revenue shortfall, driven largely by lower grant and collaboration activity, highlights the gap that emerging product sales must still fill before recurring revenue can stabilize the company's top line.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on whether Dyadic can convert early customer sampling into recurring orders. The company recorded its first direct commercial sales of recombinant transferrin and DNase I during the quarter, but management has acknowledged that qualification and adoption timelines are running longer than originally anticipated. The conversion of initial purchases into repeat business will be a central metric in coming quarters.

Partnership-driven revenue remains another key watch item. Partner Proliant Health and Biologicals continues to expand commercial activities around AlbuFree DX recombinant human albumin, while Inzymes has now commercialized a second chymosin product, which should generate a $225,000 payment recognized in the fourth quarter of 2026. Distribution agreements, including a new portfolio of research-use-only products launched through IBT Bioservices, add further channels for near-term revenue.

On the cost side, the company's declining R&D and G&A expenses reflect a leaner operating structure, but sustained losses mean cash runway and potential financing activity will remain important considerations. Dyadic has previously indicated that current cash resources are expected to provide runway into 2027, with disciplined spending prioritized toward high-impact programs and grant-funded activities. Margin trends, grant activity, and the cadence of new partner milestones will all shape how the market interprets the company's path toward commercial scale.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations